Literature DB >> 32575937

[Progress in diagnosis and treatment of rectal neuroendocrine neoplasms].

Z J Wu1, M Y Zhou1, Z X Zheng1, J J Bi1, X S Wang1, Q Feng1.   

Abstract

Neuroendocrine neoplasms (NENs) are relatively rare heterogeneous tumors that originate from peptidergic neurons and neuroendocrine cells and have been referred to as "carcinoids" in the past. Although this type of tumor had been previously considered to be indolent tumor with a low degree of malignancy, with the development of medicine and clinical study, researchers found that NENs had the potential to metastasize. They can occur in any part of the body where neuroendocrine cells are distributed and gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) are the most common type of NENs.Due to the improvement of techniques such as endoscopy and imaging, the incidence of rectal neuroendocrine tumors(R-NENs) and the number of related clinical researches have both increased significantly in recent years. Although researches in Chinese and foreign medical centers are mostly retrospective studies of small samples and the efficacies of different treatment methods are still under debating and lack of sufficient medical evidence to support, the diagnosis and treatment of this disease is gradually becoming standardized according to the proposal of corresponding guidelines. The recent advances in the epidemiology, diagnosis and treatment of rectal neuroendocrine neoplasms are reviewed in this paper.

Entities:  

Keywords:  Accessory examinations; Neuroendocrine neoplasms; Pathological diagnosis; Prognostic factors; Rectal neoplasms; Treatment

Year:  2020        PMID: 32575937     DOI: 10.3760/cma.j.cn112152-20190820-00539

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  1 in total

1.  Risk factors for lymph node metastasis and prognosis in colorectal neuroendocrine tumours.

Authors:  Xiuli Zheng; Mingli Wu; Limian Er; Huiyan Deng; Gongning Wang; Lingyao Jin; Shengmian Li
Journal:  Int J Colorectal Dis       Date:  2022-01-08       Impact factor: 2.571

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.